疏风解毒胶囊联合双支气管扩张剂治疗痰热壅肺型老年慢性阻塞性肺疾病急性加重期的临床疗效及安全性分析

Clinical efficacy and safety analysis of Shufeng Jiedu Capsule combined with bibronchiectasis in the treatment of elderly AECOPD patients in syndrome of phlegm-heat obstructing lung

目的:探讨疏风解毒胶囊联合双支气管扩张剂治疗痰热壅肺型老年慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效及安全性。方法:选取2018年5月-2019年5月本院收治的老年AECOPD患者98例,根据随机数字表法将其分为对照组49例(双支气管扩张剂)和联合组49例(疏风解毒胶囊联合双支气管扩张剂)。记录两组患者治疗前后肺功能指标、炎性因子指标、氧化应激反应指标以及临床效果并进行比较。结果:治疗后,联合组患者FEV1、FVC及FEV1/FVC均显著高于对照组(P<0.05),hs-CRP、TNF-α及IL-8均显著低于对照组(P<0.05),MDA显著低于对照组,而GSH-Px及SOD均显著高于对照组(P<0.05)。联合组治疗总有效率(95.92%,47/49)显著高于对照组(73.47%,36/49)(P<0.05)。结论:疏风解毒胶囊联合双支气管扩张剂治疗痰热壅肺型老年AECOPD患者疗效更为显著,可有效改善患者肺功能,减轻炎性反应、氧化应激反应,值得在临床进行推广应用。

Objective: To discuss the clinical efficacy and safety analysis of Shufeng Jiedu Capsule combined with bibronchiectasis in the treatment of elderly acute exacerbation chronic obstructive pulmonary disease(AECOPD) patients in syndrome of phlegm-heat obstructing lung. Methods: A total of 98 elderly AECOPD patients in our hospital form May 2018 to May 2019 were selected, according to the random number table method, all patients were divided into the control group with 49 cases(treated with bibronchiectasis) and the combined group with 49 cases(treated with Shufeng Jiedu Capsule combined with bibronchiectasis). The pulmonary function indicators, inflammatory factor indicators, oxidative stress response indicators before and after treatment and clinical effect were recorded and compared. Results: The FEV1, FVC and FEV1/FVC of the combined group after treatment were significantly higher than the control group(P<0.05). The high sensitivity C-reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α) and interleukin-8(IL-8) of the combined group after treatment were significantly lower than the control group(P<0.05). After treatment, the malondialdehyde(MDA) of the combined group was significantly lower than that in the control group, the glutathione peroxidase(GSH-Px) and superoxide dismutase(SOD) of the combined group were significantly higher than those in the control group(P<0.05). The total effective rate of the combined group was 95.92%(47/49), which was significantly higher than 73.47%(36/49) in the control group(P<0.05). Conclusion: The curative effect of Shufeng Jiedu Capsule combined with bibronchiectasis in the treatment of elderly AECOPD patients is more significant, and can effectively improve pulmonary function, alleviate oxidative stress and inflammatory reaction, which is worth popularizing and applying in clinic.